Friday, 22 October 2021

Tag Archives: Swiss drugmaker

Roche ‘disappointed’ with trial results for colitis drug

ZURICH: Roche Holding’s experimental drug etrolizumab did not fare well in late-stage clinical trials in treating people with moderate to severe ulcerative colitis, the Swiss drugmaker said. “Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to ...

Read More »